Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M200Revenue $M0.3Net Margin (%)-34,619.9Altman Z-Score0.4
Enterprise Value $M124EPS $-1.5Operating Margin %-35,233.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.8Pre-tax Margin (%)-34,619.1Higher ROA y-yY
Price/Book2.210-y EBITDA Growth Rate %-18.3Quick Ratio6.7Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %6.0Current Ratio6.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-62.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-70.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M59.6ROIC % (ttm)-450.7Gross Margin Increase y-yN

Gurus Latest Trades with ARWR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARWRGeorge Soros 2014-06-30 Sold Out -0.01%$9.79 - $18.28
($13.09)
$ 3.36-74%Sold Out0
ARWRGeorge Soros 2014-03-31 Buy 0.01%$9.92 - $26.57
($17.36)
$ 3.36-81%New holding44,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARWR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ARWR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myszkowski Kenneth AllenCFO 2015-12-30Sell23,347$6.13-45.19view
Lewis David L.Chief Scientific Officer 2015-01-05Sell15,000$8.01-58.05view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-46.84view
Anzalone Christopher RichardPresident and CEO 2014-10-15Buy16,000$6.32-46.84view
McKenney CharlesDirector 2014-10-01Sell2,500$14.7-77.14view
Lewis David L.Chief Scientific Officer 2014-09-30Sell15,000$15.02-77.63view
GIVEN DOUGLAS BDirector 2014-09-26Sell2,000$15.24-77.95view
GIVEN DOUGLAS BDirector 2014-08-15Sell5,000$13.9-75.83view
Myszkowski Kenneth AllenCFO 2014-08-15Sell40,000$14.02-76.03view
McKenney CharlesDirector 2014-06-09Sell22,000$14.32-76.54view

Quarterly/Annual Reports about ARWR:

News about ARWR:

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
ARROWHEAD RESEARCH CORP Financials Feb 13 2016
Arrowhead Research reports 1Q loss Feb 09 2016
Arrowhead Research reports 1Q loss Feb 09 2016
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 09 2016
Arrowhead Reports Fiscal 2016 First Quarter Results Feb 09 2016
Q1 2016 Arrowhead Research Corp Earnings Release - After Market Close Feb 09 2016
Arrowhead to Webcast Fiscal 2016 First Quarter Results Feb 02 2016
Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation Jan 19 2016
Arrowhead’s ARC-AAT Granted EMA Orphan Drug Designation Jan 19 2016
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jan 14 2016
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express Jan 13 2016
Arrowhead Research Corp. breached its 50 day moving average in a Bearish Manner : January 7, 2016 Jan 07 2016
Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic... Jan 07 2016
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
5 Stocks Ready for Breakouts Dec 18 2015
Pre-market Equity Watch on Biotechnology -- Agenus, Arrowhead Research, Spectrum Pharma, and... Dec 18 2015
Edited Transcript of ARWR earnings conference call or presentation 14-Dec-15 9:30pm GMT Dec 15 2015
Arrowhead Research reports 4Q loss Dec 14 2015
Arrowhead Research reports 4Q loss Dec 14 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

Truthtracer@twitter
ReplyTruthtracer@twitter - 2 years ago
Correction, carefully read the scientific foundation shared in the 4th quarter report.
Truthtracer@twitter
ReplyTruthtracer@twitter - 2 years ago
Pay attention to the science in the third quarter report. Institutional holdings have increased from 30% to over 70% in 3 months. Reputable, longer term holders...
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK